Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
| Ticker |
Sentiment |
Impact |
|
KRYS
|
Neutral
|
12 %
|
|
GILD
|
Somewhat Bullish
|
23 %
|
|
GSK
|
Neutral
|
16 %
|
|
PFE
|
Neutral
|
4 %
|
|
FULC
|
Neutral
|
12 %
|
|
SGIOF
|
Neutral
|
4 %
|
